Performance of capecitabine in novel combination therapies in colorectal cancer

Abstract

Colorectal cancer is one of the most common cancers throughout the world, and no definitive cure has ever been found. Perhaps a new insight into the effectiveness of chemotherapy drugs could help better treat patients. Targeted therapies have significantly improved the median overall survival of colorectal cancer patients. One of the standard chemotherapy regimens used for colorectal cancer is capecitabine, which is important in monotherapy and combination therapies. Capecitabine, with other chemotherapeutic agents (irinotecan, oxaliplatin, perifosine, 17-allylamino-17-demethoxygeldanamycin, aspirin, celecoxib, statins, quinacrine, inositol hexaphosphate and inositol, cystine/theanine, curcumin, and isorhamnetin), and biological ones (antibodies) plays an important role in the inhibition of some signaling pathways, increasing survival, reducing tumor growth and side effects of capecitabine. However, some drugs, such as proton pump inhibitors, are negatively related to capecitabine; therefore, the purpose of this work is to review and discuss the performance of capecitabine combination therapies in colorectal cancer.

Keywords:

• Colorectal cancer
• capecitabine
• combination therapy

Acknowledgment

A sincere thank you to Naser Danesh Pouya for his diligent proofreading of this study.

Author’s contributions

FDP and YR conceived and designed the study; FDP wrote the manuscript draft; YR, YT, IYC, and MN critically reviewed the manuscript. All authors approved the final version of the manuscript.

Disclosure statement

The authors declare that there are no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Additional information

Notes on contributors

Fahima Danesh Pouya

Fahima Danesh Pouya is PhD of Clinical Biochemistry at the Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Yousef Rasmi

Dr. Yousef Rasmi is PhD of Clinical Biochemistry, Professor at the Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. His research interests are related to cell signaling, nanomedicine, and cancer.

Irem Yalim Camci

Dr. Irem Yalim Camci is a Researcher Cancer at the Department of Molecular Biology and Genetics, Faculty of Science, Gebze Technical University, Kocaeli, Turkey.

Yusuf Tutar

Dr.Yusuf Tutar is a Professor at the Division of Biochemistry, Department of Basic Pharmaceutical Sciences, Hamidiye Faculty of Pharmacy, University of Health Sciences, Istanbul, Turkey. His research interests are related to drug design, molecular cancer, and noncoding RNA.

Mohadeseh Nemati

Mohadeseh Nemati is PhD of Clinical Biochemistry at the Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.